
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
 "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">

<html xmlns="http://www.w3.org/1999/xhtml" lang="en">

<head>
<meta name="google-site-verification" content="tpATPqNEN3HXiSbtqevBE9NdgbuCiN9Vmr6EP94lx6w" />
<meta name="keywords" content="keywords" />
<meta name="description" content="page description" />
<title>D | Office of Evaluation and Inspections | Reports & Publications | Office of Inspector General | U.S. Department of Health and Human Services</title>
<!--#include virtual="/layout/head.asp" -->


<!-------------/ head closes and body opens, this frees us to add content outside the UI structure / --->

<!--#include virtual="/layout/head-body-tags.asp" -->

<!------------/ head closes and body opens / --->


<div id="bodyContainer">
	<div id="textReset">
	<!--#include virtual="/layout/header.asp" -->

			<div id="mainBody">
			<div id="leftSideInterior">
				<div id="breadcrumbs">
					<ul>
						<li>
							<a href="/">Home</a>
						</li>
						<li>
							<a href="/reports-and-publications/index.asp">Reports &amp; Publications</a>
						</li>	
	
						<li>
							<a href="/reports-and-publications/oei/subject_index.asp">Office of Evaluation and Inspections</a>
						</li>
						<li>
						 D
						</li>
					
					</ul>

				</div>
				<div id="leftContentInterior">
					<h1>D | Office of Evaluation and Inspections</h1>
					<div class="featuredContent">
								<table cellpadding="0" cellspacing="0" border="0" class="onthispage flush_top no_print">
<tr valign="top"><th colspan="3" scope="col">Topics:</th></tr>
<tr valign="top">
<td>
<ul class="flush_list overlinked">
<li><a href="#data_banks">Data Banks/Data Systems</a></li>
<li><a href="#dental">Dental and Dentists</a></li>
<li><a href="#detox">Detoxification Services</a></li>
<li><a href="#drg">Diagnosis Related Groups</a></li>
<li><a href="#dietary_suppliments">Dietary Supplements</a></li>
</ul>
</td><td>
<ul class="flush_list overlinked">
<li><a href="#disability">Disability</a></li>
<li><a href="#disaster">Disaster Relief</a></li>
<li><a href="#dg">Discretionary Grants</a></li>
<li><a href="#dea">Drug Enforcement Administration</a></li>
</ul>
</td><td>
<ul class="flush_list overlinked">
<li><a href="#drugs">Drugs and Drug Industry</a></li>
<li><a href="#durp">Drug Use Review Programs</a></li>
<li><a href="#dumping">Dumping</a></li>
<li><a href="#dmerc">Durable Medical Equipment Regional Carriers</a></li>
</ul>
</td>
</tr></table>
	


						<a class="back" href="/reports-and-publications/oei/subject_index.asp">Return to OEI Reports Subject Index</a>
					<div class="clear"></div>
					</div>	

<!-- PDF Notification -->
<!--#include virtual="/layout/all_pdf.asp" -->

<!-- OEI Subject Box -->
<div id="oei_subjects">


<h2><a name="data_banks"></a>Data Banks/Data Systems</h2> 
<ul class="simplegray lowmargin overlinked">
<li class="crossref">see also: <a href="/reports-and-publications/oei/n.asp#npdb">National Practitioner Data Bank</a></li>
<li><a href="/oei/reports/oei-01-14-00570.asp">Hospitals Largely Reported Addressing Requirements for EHR Contingency Plans</a>&nbsp;<cite>(OEI-01-14-00570)</cite></li>
<li><a href="/oei/reports/oei-09-10-00510.asp">OCR Should Strengthen Its Oversight of Covered Entities' Compliance With the HIPAA Privacy Standards</a>&nbsp;<cite>(OEI-09-10-00510)</cite></li> 
<li><a href="/oei/reports/oei-09-10-00511.asp">OCR Should Strengthen Its Followup of Breaches of Patient Health Information Reported by Covered Entities</a>&nbsp;<cite>(OEI-09-10-00511)</cite></li>
<li><a href="/oei/reports/oei-07-13-00120.asp">Not All States Reported Medicaid Managed Care Encounter Data as Required</a>&nbsp;<cite>(OEI-07-13-00120)</cite></li>
<li><a href="/oei/reports/oei-03-14-00230.asp">Federal Marketplace:  Inadequacies in Contract Planning and Procurement</a>&nbsp;<cite>(OEI-03-14-00230)</cite></li>
<li><a href="/oei/reports/oei-01-14-00180.asp">Marketplaces Faced Early Challenges Resolving Inconsistencies With Applicant Data</a>&nbsp;<cite>(OEI-01-14-00180)</cite></li>
<li><a href="/oei/reports/oei-04-10-00181.asp">Improper Payments for Evaluation and Management Services Cost Medicare Billions in 2010</a>&nbsp;<cite>(OEI-04-10-00181)</cite></li>
<li><a href="/oei/reports/oei-06-12-00031.asp">CMS System for Sharing Information About Terminated Providers Needs Improvement</a>&nbsp;<cite>(OEI-06-12-00031)</cite></li>
<li><a publish_date="03/03/2014" href="/oei/reports/oei-03-11-00720.asp">CMS Regularly Reviews Part C Reporting Requirements Data, But Its Followup and Use of the Data Are Limited</a>&nbsp;<cite>(OEI-03-11-00720)</cite></li>
<li><a href="/oei/reports/oei-09-11-00430.asp">Disclosure and Accounting of Protected Records by CMS Between 2006 and 2011</a>&nbsp;<cite>(OEI-09-11-00430)</cite></li> 
<li><a href="/oei/reports/oei-09-11-00380.asp">Progress in Electronic Health Record Implementation Through HRSA Grants to Health Center Controlled Networks</a>&nbsp;<cite>(OEI-09-11-00380)</cite></li>
<li><a href="/oei/reports/oei-01-11-00570.asp">Not All Recommended Fraud Safeguards Have Been Implemented in Hospital EHR Technology</a>&nbsp;<cite>(OEI-01-11-00570)</cite></li>
<li><a href="/oei/reports/oei-05-12-00610.asp">Early Outcomes Show Limited Progress for the Transformed Medicaid Statistical Information System</a>&nbsp;<cite>(OEI-05-12-00610)</cite></li> 
<li><a publish_date="05/28/2013" href="/oei/reports/oei-07-09-00440.asp">Improvements Are Needed To Ensure Provider Enumeration and Medicare Enrollment Data Are Accurate, Complete, and Consistent</a>&nbsp;<cite>(OEI 07-09-00440)</cite></li>
<li><a publish_date="11/28/2012" href="/oei/reports/oei-05-11-00250.asp">Early Assessment Finds That CMS Faces Obstacles in Overseeing the Medicare EHR Incentive Program</a>&nbsp;<cite>(OEI-05-11-00250)</cite></li>
<li><a publish_date="09/12/2012" href="/oei/reports/oei-07-09-00292.asp">CMS Reporting to the Healthcare Integrity and Protection Data Bank</a>&nbsp;<cite>(OEI-07-09-00292)</cite></li>
<li><a href="/oei/reports/oei-06-09-00092.asp">Few Adverse Events in Hospitals Were Reported to State Adverse Event Reporting Systems</a>&nbsp;<cite>(OEI-06-09-00092)</cite></li>
<li><a publish_date="06/21/2012" href="/oei/reports/oei-04-10-00184.asp">Use of Electronic Health Record Systems in 2011 Among Medicare Physicians Providing Evaluation and Management Services</a>&nbsp;<cite>(OEI-04-10-00184)</cite></li>
<li><a publish_date="04/17/2012" href="/oei/reports/oei-09-08-00370.asp">The Medicare-Medicaid (Medi-Medi) Data Match Program</a>&nbsp;<cite>(OEI-09-08-00370)</cite></li>
<li><a publish_date="02/27/2012" href="/oei/reports/oei-01-10-00460.asp">Limited Oversight of Home Health Agency OASIS Data</a>&nbsp;<cite>(OEI-01-10-00460)</cite></li>
<li><a publish_date="01/26/2012" href="/oei/reports/oei-07-11-00340.asp">Lack of Data Regarding Physicians Opting Out of Medicare</a>&nbsp;<cite>(OEI-07-11-00340)</cite></li>
<li><a publish_date="01/05/2012" href="/oei/reports/oei-06-09-00091.asp">Hospital Incident Reporting Systems Do Not Capture Most Patient Harm</a>&nbsp;<cite>(OEI-06-09-00091)</cite></li>
<li><a href="/oei/reports/oei-05-96-00260.pdf">Results-Based Systems for Public Health Programs, Volume 1: Lessons from State Initiatives</a> <cite>(OEI-05-96-00260; 9/97)</cite></li>
<li><a href="/oei/reports/oei-05-96-00261.pdf">Results-Based Systems for Public Health Programs, Volume 2: State Case Studies</a> <cite>(OEI-05-96-00261; 9/97)</cite></li>
<li><a href="/oei/reports/oei-07-95-00030.pdf">Surveillance and Utilization Review Subsystem Referrals</a> <cite>(OEI-07-95-00030; 11/96)</cite></li>
<li><a href="/oei/reports/oei-04-96-00010.pdf">Implementation of State Child Support Certified Data Systems</a> <cite>(OEI-04-96-00010; 4/97)</cite></li>
</ul>



<p><a name="dental"></a>
 <a class="back"  href="/reports-and-publications/oei/subject_index.asp#D" title="Go back">Back</a>  <a class="top"  href="#top">Top</a></p>
<!--===============  [ *** ]  ===============-->
<h2>Dental and Dentists</h2>
<ul class="simplegray lowmargin overlinked">
<li><a href="/oei/reports/oei-02-14-00490.asp">Most Children With Medicaid in Four States Are Not Receiving Required Dental Services</a>&nbsp;<cite>(OEI-02-14-00490)</cite></li>  
<li><a href="/oei/reports/oei-02-14-00480.asp">Questionable Billing for Medicaid Pediatric Dental Services in California</a>&nbsp;<cite>(OEI-02-14-00480)</cite></li>
<li><a href="/oei/reports/oei-02-14-00250.asp">Questionable Billing for Medicaid Pediatric Dental Services in Indiana</a>&nbsp;<cite>(OEI-02-14-00250)</cite></li>
<li><a href="/oei/reports/oei-02-12-00330.asp">Questionable Billing for Medicaid Pediatric Dental Services in New York</a>&nbsp;<cite>(OEI-02-12-00330)</cite></li>
<li><a href="/oei/reports/oei-04-04-00210.pdf">Improper Payments for Medicaid Pediatric Dental Services</a> <cite>(OEI-04-04-00210)</cite></li>
<li><a href="/oei/reports/oei-09-93-00240.pdf">Children's Dental Services Under Medicaid: Access and Utilization</a> <cite>(OEI-09-93-00240; 4/96)</cite></li>
<li><a href="/oei/reports/oei-01-92-00820.pdf">The Licensure of Out-of-State Dentists</a> <cite>(OEI-01-92-00820; 8/93)</cite></li>
<li><a href="/oei/reports/oei-01-92-00821.pdf">State Dental Boards and Dental Discipline</a> <cite>(OEI-01-92-00821; 8/93)</cite></li>
<li><a href="/oei/reports/oai-01-88-00580.pdf">State Licensure and Discipline of Dentists</a> <cite>(OAI-01-88-00580; 8/88)</cite></li>
</ul>


<p><a name="detox"></a>
 <a class="back"  href="/reports-and-publications/oei/subject_index.asp#D" title="Go back">Back</a>  <a class="top"  href="#top">Top</a></p>
<!--===============  [ *** ]  ===============-->
<h2>Detoxification Services</h2> 
<ul class="simplegray lowmargin overlinked">
<li class="crossref">see also: <a href="/reports-and-publications/oei/s.asp#substance_abuse">Substance Abuse</a></li>
<li><a href="/oei/reports/oei-07-97-00270.pdf">Follow-up to Detoxification Services for Medicaid Beneficiaries</a> <cite>(OEI-07-97-00270; 11/98)</cite></li>
</ul>


<p><a name="devices"></a>
 <a class="back"  href="/reports-and-publications/oei/subject_index.asp#D" title="Go back">Back</a>  <a class="top"  href="#top">Top</a></p>
<!--===============  [ *** ]  ===============-->
<h2>Devices</h2> 
<ul class="simplegray lowmargin overlinked">
<li class="crossref">see <a href="/reports-and-publications/oei/m.asp#mde">Medical Devices and Equipment</a></li>
</ul>



<p><a name="drg"></a>
 <a class="back"  href="/reports-and-publications/oei/subject_index.asp#D" title="Go back">Back</a>  <a class="top"  href="#top">Top</a></p>
<!--===============  [ *** ]  ===============-->
<h2>Diagnosis Related Groups (DRGs)</h2>
<ul class="simplegray lowmargin overlinked">
<li><a href="/oei/reports/oei-09-14-00440.asp">Inconsistencies in State Implementation of Correct Coding Edits May Allow Improper Medicaid Payments</a>&nbsp;<cite>(OEI-09-14-00440)</cite></li>
<li><a href="/oei/reports/oei-05-12-00480.asp">Medicare and Beneficiaries Could Realize Substantial Savings If the DRG Window Were Expanded</a>&nbsp;<cite>(OEI-05-12-00480)</cite></li>
<li><a href="/oei/reports/oei-05-12-00340.asp">Questionable Billing for Polysomnography Services</a>&nbsp;<cite>(OEI-05-12-00340)</cite></li>
<li><a href="/oei/reports/oei-04-10-00180.asp">Coding Trends of Medicare Evaluation and Management Services</a>&nbsp;<cite>(OEI-04-10-00180)</cite></li>
<li><a href="/oei/reports/oei-09-00-00200.pdf">Medicare Hospital Prospective Payment System: How DRG Rates Are Calculated and Updated</a> <cite>(OEI-09-00-00200; 08/01)</cite></li>
<li><a href="/oei/reports/oei-03-99-00240.pdf">Medicare Payments for DRG 014: Specific Cerebrovascular Disorders Except Transient Ischemic Attack</a> <cite>(OEI-03-99-00240; 7/99)</cite></li>
<li><a href="/oei/reports/oei-03-98-00490.pdf">Medicare Payments for DRG 296: Nutritional and Miscellaneous Metabolic Disorders</a> <cite>(OEI-03-98-00490; 4/99)</cite></li>
<li><a href="/oei/reports/oei-03-98-00370.pdf">Medicare Payments for Septicemia</a> <cite>(OEI-03-98-00370; 4/99)</cite></li>
<li><a href="/oei/reports/oei-03-98-00560.pdf">Medicare Payments for DRG 475: Respiratory System Diagnosis with Ventilator Support</a> <cite>(OEI- 03-98-00560; 1/99)</cite></li>
<li><a href="/oei/reports/oei-01-98-00420.pdf">Monitoring the Accuracy of Hospital Coding</a> <cite>(OEI-01-98-00420; 1/99)</cite></li>
<li><a href="/oei/reports/oei-01-97-00010.pdf">Using Software to Detect Upcoding of Hospital Bills</a> <cite>(OEI-01-97-00010; 8/98)</cite></li>
<li><a href="/oei/reports/oei-12-89-00193.pdf">DRG 79 Validation Study Update: Respiratory Infections and Inflammations</a> <cite>(OEI-12-89-00193; 9/93)</cite></li>
<li><a href="/oei/reports/oei-12-89-00196.pdf">DRG 154 Validation: Stomach, Esophageal, and Duodenal</a> <cite>(OEI-12-89-00196; 12/93)</cite></li>
<li><a href="/oei/reports/oei-12-89-00194.pdf">DRG 121 Validation: Circulatory Disorders</a> <cite>(OEI-12-89-00194; 10/92)</cite></li>
<li><a href="/oei/reports/oei-12-89-00195.pdf">DRG 296 Validation: Metabolic Disorders</a> <cite>(OEI-12-89-00195; 10/92)</cite></li>
<li><a href="/oei/reports/oei-12-89-00190.pdf">National DRG Validation Study Update: Summary Report</a> <cite>(OEI-12-89-00190; 8/92)</cite></li>
<li><a href="/oei/reports/oei-12-89-00191.pdf">National DRG Validation Study Update: Technical Report</a> <cite>(OEI-12-89-00191; 8/92)</cite></li>
<li><a href="/oei/reports/oei-12-89-00192.pdf">DRG 14 Validation Update: Specific Cerebrovascular Disorders Except Transient Ischemic Attacks</a> <cite>(OEI-12-89-00192; 8/92)</cite></li>
<li><a href="/oei/reports/oei-12-90-00660.pdf">FY 1985 National DRG Validation Study: Peer Review Organization Coding Accuracy</a> <cite>(OEI-12-90-00660; 8/90)</cite></li>
<li><a href="/oei/reports/oai-12-88-01170.pdf">DRG 468: Unrelated Operating Room Procedures</a> <cite>(OAI-12-88-01170; 9/89)</cite></li>
<li><a href="/oei/reports/oai-12-88-01190.pdf">DRG 79: Respiratory Infection</a> <cite>(OAI-12-88-01190; 7/89)</cite></li>
<li><a href="/oei/reports/oai-09-88-00870.pdf">National DRG Validation Study: Quality of Patient Care in Hospitals</a> <cite>(OAI-09-88-00870; 8/89)</cite></li>
<li><a href="/oei/reports/oai-12-88-01200.pdf">DRG 87: Pulmonary Edema and Respiratory Failure</a> <cite>(OAI-12-88-01200; 8/89)</cite></li>
<li><a href="/oei/reports/oai-12-88-01210.pdf">DRG 121: Circulatory Disorders with Acute Myocardial Infarction and Cardiovascular Complications</a> <cite>(OAI-12-88-01210; 8/89)</cite></li>
<li><a href="/oei/reports/oai-12-88-01160.pdf">DRG 154: Stomach, Esophageal, and Duodenal Procedures</a> <cite>(OAI-12-88-01160; 8/89)</cite></li>
<li><a href="/oei/reports/oai-12-88-01180.pdf">DRG 416: Septicemia</a> <cite>(OAI-12-88-01180; 8/89)</cite></li>
<li><a href="/oei/reports/oai-12-88-01140.pdf">DRG 89: Simple Pneumonia and Pleurisy</a> <cite>(OAI-12-88-01140; 6/89)</cite></li>
<li><a href="/oei/reports/oai-05-88-00730.pdf">National DRG Validation Study: Short Hospitalizations</a> <cite>(OAI-05-88-00730; 5/89)</cite></li>
<li><a href="/oei/reports/oai-09-88-00880.pdf">National DRG Validation Study: Unnecessary Admissions to Hospitals</a> <cite>(OAI-09-88-00880; 8/88)</cite></li>
<li><a href="/oei/reports/oai-12-88-01010.pdf">National DRG Validation Study: Coding Accuracy</a> <cite>(OAI-12-88-01010; 2/88)</cite></li>
<li><a href="/oei/reports/oai-05-88-00740.pdf">National DRG Validation Study: Premature Discharges</a> <cite>(OAI-05-88-00740; 2/88)</cite></li>
<li><a href="/oei/reports/oai-09-86-00052.pdf">Validation of DRG 14</a> <cite>(OAI-09-86-00052; 12/87)</cite></li>
</ul>


<p>
 <a class="back"  href="/reports-and-publications/oei/subject_index.asp#D" title="Go back">Back</a>  <a class="top"  href="#top">Top</a></p>
<!--===============  [ *** ]  ===============-->
<h2>Dialysis and Dialysis Facilities</h2> 
<ul class="simplegray lowmargin overlinked">
<li class="crossref">see: <a href="/reports-and-publications/oei/e.asp#esrd">End-Stage Renal Disease</a></li>
</ul>



<p><a name="dietary_suppliments"></a>
 <a class="back"  href="/reports-and-publications/oei/subject_index.asp#D" title="Go back">Back</a>  <a class="top"  href="#top">Top</a></p>
<!--===============  [ *** ]  ===============-->
<h2>Dietary Supplements</h2>
<ul class="simplegray lowmargin overlinked">
<li><a href="/oei/reports/oei-01-11-00210.asp">Dietary Supplements: Structure/Function Claims Fail To Meet Federal Requirements</a>&nbsp;<cite>(OEI-01-11-00210)</cite></li> 
<li><a href="/oei/reports/oei-01-11-00211.asp">Dietary Supplements: Companies May Be Difficult To Locate in an Emergency</a>&nbsp;<cite>(OEI-01-11-00211)</cite></li>
<li><a href="/oei/reports/oei-01-01-00120.pdf">Dietary Supplement Labels: Key Elements</a> <cite>(OEI-01-01-00120; 03/03)</cite></li>
<li><a href="/oei/reports/oei-01-01-00121.pdf">Dietary Supplement Labels: An Assessment</a> <cite>(OEI-01-01-00121; 03/03)</cite></li>
<li><a href="/oei/reports/oei-01-00-00180.pdf">Adverse Event Reporting System for Dietary Supplements: An Inadequate Safety Valve</a> <cite>(OEI-01-00-00180; 04/01)</cite></li>
</ul>


<p><a name="disability"></a>
 <a class="back"  href="/reports-and-publications/oei/subject_index.asp#D" title="Go back">Back</a>  <a class="top"  href="#top">Top</a></p>
<!--===============  [ *** ]  ===============-->
<h2>Disability</h2>
<ul class="simplegray lowmargin overlinked">
<li><a publish_date="06/21/2012" href="/oei/reports/oei-02-08-00170.asp">Oversight of Quality of Care in Medicaid Home and Community Based Services Waiver Programs</a>&nbsp;<cite>(OEI-02-08-00170)</cite></li>
<li><a href="/oei/reports/oei-07-98-00260.pdf">Employment Programs for Persons with Developmental Disabilities</a> <cite>(OEI-07-98-00260; 8/99)</cite></li>
<li><a href="/oei/reports/oei-06-95-00434.pdf">Perspectives of Medicare Risk HMOs 1996: Beneficiaries With Functional Limitations, Comorbidities and Disabilities</a> <cite>(OEI-06-95-00434; 8/98)</cite></li>
<li><a href="/oei/reports/oei-05-95-00400.pdf">Cost Containment for Medicaid Disability Programs</a> <cite>(OEI-05-95-00400; 7/97)</cite></li>
<li><a href="/oei/reports/oei-06-89-00903.pdf">Using Social Security Records to Detect Inappropriate Medicare Payments for Work-Related Disability Expenses</a> <cite>(OEI-06-89-00903; 8/94)</cite></li>
<li><a href="/oei/reports/oai-06-86-00067.pdf">Propriety of Physicians' Receipt of Federal Payments</a> <cite>(OAI-06-86-00067; 10/86)</cite></li>
</ul>



<p><a name="disaster"></a>
 <a class="back"  href="/reports-and-publications/oei/subject_index.asp#D" title="Go back">Back</a>  <a class="top"  href="#top">Top</a></p>
<!--===============  [ *** ]  ===============-->
<h2>Disaster Relief</h2>
<ul class="simplegray lowmargin overlinked">
<li><a href="/oei/reports/oei-09-90-01040.pdf">Coping With Twin Disasters: HHS Response to the 1989 Hurricane and Earthquake</a> <cite>(OEI-09-90-01040; 12/90)</cite></li>
</ul>



<p>
 <a class="back"  href="/reports-and-publications/oei/subject_index.asp#D" title="Go back">Back</a>  <a class="top"  href="#top">Top</a></p>
<!--===============  [ *** ]  ===============-->
<h2>Discharge</h2> 
<ul class="simplegray lowmargin overlinked">
<li class="crossref">see: <a href="#dumping">Dumping</a></li>
</ul>



<p><a name="dg"></a>
 <a class="back"  href="/reports-and-publications/oei/subject_index.asp#D" title="Go back">Back</a>  <a class="top"  href="#top">Top</a></p>
<!--===============  [ *** ]  ===============-->
<h2>Discretionary Grants</h2>
<ul class="simplegray lowmargin overlinked">
<li><a href="/oei/reports/oei-04-89-00801.pdf">Time Extensions and Funding Supplements for OHDS Discretionary Grants</a> <cite>(OEI-04-89-00801; 6/92)</cite></li>
</ul>



<p>
 <a class="back"  href="/reports-and-publications/oei/subject_index.asp#D" title="Go back">Back</a>  <a class="top"  href="#top">Top</a></p>
<!--===============  [ *** ]  ===============-->
<h2>Drug Abuse</h2>
<ul class="simplegray lowmargin overlinked">
<li class="crossref">see: <a href="/reports-and-publications/oei/s.asp#substance_abuse">Substance Abuse</a></li>
</ul>



<p><a name="dea"></a>
 <a class="back"  href="/reports-and-publications/oei/subject_index.asp#D" title="Go back">Back</a>  <a class="top"  href="#top">Top</a></p>
<!--===============  [ *** ]  ===============-->
<h2>Drug Enforcement Administration (DEA)</h2>
<ul class="simplegray lowmargin overlinked">
<li><a href="/oei/reports/oei-12-96-00160.pdf">Drug Enforcement Administration Report to the National Practitioner Data Bank</a> <cite>(OEI-12-96-00160; 3/97)</cite></li>
</ul>




<p><a name="drugs"></a>
 <a class="back"  href="/reports-and-publications/oei/subject_index.asp#D" title="Go back">Back</a>  <a class="top"  href="#top">Top</a></p>
<!--===============  [ *** ]  ===============-->
<h2>Drugs and Drug Industry</h2>
<ul class="simplegray lowmargin overlinked">
<li><a href="/oei/reports/oei-02-16-00270.asp">High-Price Drugs Are Increasing Federal Payments for Medicare Part D Catastrophic Coverage</a>&nbsp;<cite>(OEI-02-16-00270)</cite></li>
<li><a href="/oei/reports/oei-12-16-00340.asp">CMS Should Address Medicare's Flawed Payment System for DME Infusion Drugs Report</a>&nbsp;<cite>(OEI-12-16-00340)</cite></li>
<li><a href="/oei/reports/oei-03-13-00450.asp">MACs Continue to Use Different Methods to Determine Drug Coverage</a>&nbsp;<cite>(OEI-03-13-00450)</cite></li>
<li><a href="/oei/reports/oei-05-16-00090.asp">Part D Plans Generally Include Drugs Commonly Used by Dual Eligibles: 2016</a>&nbsp;<cite>(OEI-05-16-00090)</cite></li>
<li><a href="/oei/reports/oei-05-14-00430.asp">State Efforts to Exclude 340B Drugs from Medicaid Managed Care Rebates</a>&nbsp;<cite>(OEI-05-14-00430)</cite></li>
<li><a href="/oei/reports/oei-12-14-00030.asp">Part B Payments for 340B Purchased Drugs</a>&nbsp;<cite>(OEI-12-14-00030)</cite></li>
<li><a href="/oei/reports/oei-05-14-00431.asp">States&#39; Collection of Rebates for Drugs Paid Through Medicaid Managed Care Organizations Has Improved</a>&nbsp;<cite>(OEI-05-14-00431)</cite></li>
<li><a href="/oei/reports/oei-05-15-00120.asp">Part D Plans Generally Include Drugs Commonly Used by Dual Eligibles: 2015</a>&nbsp;<cite>(OEI-05-15-00120) </cite></li> 
<li><a href="/oei/reports/oei-01-13-00600.asp">FDA Has Made Progress on Oversight and Inspections of Manufacturers of Generic Drugs</a>&nbsp;<cite>(OEI-01-13-00600)</cite></li> 
<li><a href="/oei/reports/oei-03-13-00650.asp">Medicaid Rebates for Brand-Name Drugs Exceeded Part D Rebates by a Substantial Margin</a>&nbsp;<cite>(OEI-03-13-00650)</cite></li> 
<li><a href="/oei/reports/oei-12-15-00110.asp">Implementing OIG Recommendation Could Have Reduced Payments for DME Infusion Drugs by Hundreds of Millions of Dollars</a>&nbsp;<cite>(OEI-12-15-00110)</cite></li>
<li><a href="/oei/reports/oei-07-12-00320.asp">Second-Generation Antipsychotic Drug Use Among Medicaid-Enrolled Children: Quality-of-Care Concerns</a>&nbsp;<cite>(OEI-07-12-00320)</cite></li>
<li><a href="/oei/reports/oei-03-14-00520.asp">Comparing Average Sales Prices and Average Manufacturer Prices for Medicare Part B Drugs:  An Overview of 2013</a>&nbsp;<cite>(OEI-03-14-00520)</cite></li>
<li><a href="/oei/reports/oei-01-13-00400.asp">Medicare's Oversight of Compounded Pharmaceuticals Used in Hospitals</a>&nbsp;<cite>(OEI-01-13-00400)</cite></li>
<li><a href="/oei/reports/oei-03-12-00520.asp">States' Collection of Offset and Supplemental Medicaid Rebates</a>&nbsp;<cite>(OEI-03-12-00520)</cite></li>
<li><a href="/oei/reports/oei-02-11-00172.asp">Medicare Paid for HIV Drugs for Deceased Beneficiaries</a>&nbsp;<cite>(OEI-02-11-00172)</cite></li> 
<li><a href="/oei/reports/oei-07-13-00220.asp">Drug Compendia Publishers Maintain Transparent Processes for Evaluating Anticancer Drug Therapies and Identifying Potential Conflicts</a>&nbsp;<cite>(OEI-07-13-00220)</cite></li>
<li><a href="/oei/reports/oei-05-12-00540.asp">Manufacturer Safeguards May Not Prevent Copayment Coupon Use for Part D Drugs</a>&nbsp;<cite>(OEI-05-12-00540)</cite></li>
<li><a href="/oei/reports/oei-02-14-00120.asp">Questionable Billing for Medicaid Pediatric Dental Services in Louisiana</a>&nbsp;<cite>(OEI-02-14-00120)</cite></li>  
<li><a href="/oei/reports/oei-05-11-00580.asp">Medicaid Drug Rebate Dispute Resolution Could Be Improved</a>&nbsp;<cite>(OEI-05-11-00580)</cite></li>  
<li><a href="/oei/reports/oei-02-11-00170.asp">Part D Beneficiaries With Questionable Utilization Patterns for HIV Drugs</a>&nbsp;<cite>(OEI-02-11-00170)</cite></li>
<li><a href="/oei/reports/oei-12-13-00040.asp">Limitations in Manufacturer Reporting of Average Sales Price Data for Part B Drugs</a>&nbsp;<cite>(OEI-12-13-00040)</cite></li> 
<li><a href="/oei/reports/oei-05-14-00170.asp">Part D Plans Generally Include Drugs Commonly Used by Dual Eligibles: 2014</a>&nbsp;<cite>(OEI-05-14-00170)</cite></li>
<li><a href="/oei/reports/oei-03-13-00270.asp">Compounded Drugs Under Medicare Part B: Payment and Oversight</a>&nbsp;<cite>(OEI-03-13-00270)</cite></li>
<li><a href="/oei/reports/oei-03-12-00560.asp">Annual Fee on Branded Prescription Drug Companies Under the Affordable Care Act</a>&nbsp;<cite>(OEI-03-12-00560)</cite></li>
<li><a href="/oei/reports/oei-03-12-00550.asp">Update: Medicare Payments for End Stage Renal Disease Drugs</a>&nbsp;<cite>(OEI-03-12-00550)</cite></li>
<li><a href="/oei/reports/oei-03-13-00570.asp">Comparing Average Sales Prices and Average Manufacturer Prices for Medicare Part B Drugs: An Overview of 2012</a>&nbsp;<cite>(OEI-03-13-00570)</cite></li> 
<li><a publish_date="03/03/3014" href="/oei/reports/oei-03-13-00030.asp">Less Than Half of Part D Sponsors Voluntarily Reported Data on Potential Fraud and Abuse</a>&nbsp;<cite>(OEI-03-13-00030)</cite></li>
<li><a href="/oei/reports/oei-05-13-00431.asp">Contract Pharmacy Arrangements in the 340B Program</a>&nbsp;<cite>(OEI-05-13-00431)</cite></li>
<li><a href="/oei/reports/OEI-12-12-00260.asp">Medicare Could Collect Billions If Pharmaceutical Manufacturers Were Required To Pay Rebates for Part B Drugs</a>&nbsp;<cite>(OEI-12-12-00260)</cite></li> 
<li><a publish_date="08/29/2013" href="/oei/reports/oei-03-11-00640.asp">Medicaid Drug Pricing in State Maximum Allowable Cost Programs</a>&nbsp;<cite>(OEI-03-11-00640)</cite></li>
<li><a publish_date="06/21/2013" href="/oei/reports/oei-02-09-00608.asp">Medicare Inappropriately Paid for Drugs Ordered by Individuals Without Prescribing Authority</a>&nbsp;<cite>(OEI-02-09-00608)</cite></li>
<li><a publish_date="06/20/2013" href="/oei/reports/oei-02-09-00603.asp">Prescribers With Questionable Patterns in Medicare Part D</a>&nbsp;<cite>(OEI-02-09-00603)</cite></li>
<li><a publish_date="06/03/2013" href="/oei/reports/oei-05-13-00090.asp">Part D Plans Generally Include Drugs Commonly Used by Dual Eligible:  2013</a>&nbsp;<cite>Report  (OEI-05-13-00090)</cite></li>
<li><a href="/oei/reports/oei-01-13-00150.asp">High-Risk Compounded Sterile Preparations and Outsourcing by Hospitals That Use Them</a>&nbsp;<cite>(OEI-01-13-00150)</cite></li>
<li><a publish_date="03/04/2013" href="/oei/reports/oei-05-10-00450.asp">Gaps in Oversight of Conflicts of Interest in Medicare Prescription Drug Decisions</a>&nbsp;<cite>(OEI-05-10-00450)</cite></li>
<li><a publish_date="02/06/2013" href="/oei/reports/oei-03-12-00670.asp">Comparison of Average Sales Prices and Average Manufacturer Prices:  An Overview of 2011</a>&nbsp;<cite>(OEI-03-12-00670)</cite></li>
<li><a publish_date="02/20/2013" href="/oei/reports/oei-12-12-00310.asp">Part B Payments for Drugs Infused Through Durable Medical Equipment</a>&nbsp;<cite>(OEI-12-12-00310)</cite></li>
<li><a href="/oei/reports/OEI-04-11-00510.asp">FDA Lacks Comprehensive Data To Determine Whether Risk Evaluation and Mitigation Strategies Improve Drug Safety</a>&nbsp;<cite>(OEI-04-11-00510)</cite></li>
<li><a publish_date="01/09/2013" href="/oei/reports/oei-03-11-00310.asp">MEDIC Benefit Integrity Activities in Medicare Parts C and D</a>&nbsp;<cite>(OEI-03-11-00310)</cite></li>
<li><a href="/oei/reports/oei-03-13-00100.asp">Comparison of Second-Quarter 2012 Average Sales Prices and Average Manufacturer Prices:  Impact on Medicare Reimbursement for Fourth Quarter 2012</a>&nbsp;<cite>(OEI-03-13-00100)</cite></li> 
<li><a publish_date="12/12/2012" href="/oei/reports/oei-03-12-00730.asp">Comparison of First-Quarter 2012 Average Sales Prices and Average Manufacturer Prices:  Impact on Medicare Reimbursement for Third Quarter 2012</a>&nbsp;<cite>(OEI-03-12-00730)</cite></li>
<li><a href="/oei/reports/oei-12-12-00210.asp">Least Costly Alternative Policies:  Impact on Prostate Cancer Drugs Covered Under Medicare Part&nbsp;B</a>&nbsp;<cite>(OEI-12-12-00210) </cite></li> 
<li><a href="/oei/reports/oei-03-11-00650.asp">Analyzing Changes to Medicaid Federal Upper Limit Amounts</a>&nbsp;<cite>(OEI-03-11-00650)</cite></li>
<li><a href="/oei/reports/oei-02-09-00605.asp">Inappropriate Medicare Part D Payments for Schedule II Drugs Billed as Refills</a>&nbsp;<cite>(OEI-02-09-00605)</cite></li> 
<li><a publish_date="09/07/2012" href="/oei/reports/oei-03-11-00480.asp">States Collection of Medicaid Rebates for Drugs Paid Through Medicaid Managed Care Organizations</a>&nbsp;<cite>(OEI-03-11-00480)</cite></li>
<li><a href="/oei/reports/oei-03-12-00410.asp">Comparison of Fourth-Quarter 2011 Average Sales Prices and Average Manufacturer Prices:  Impact on Medicare Reimbursement for Second Quarter 2012</a>&nbsp;<cite>(OEI-03-12-00410)</cite></li>
<li><a href="/oei/reports/oei-07-08-00151.asp">Nursing Facility Assessments and Care Plans for Residents Receiving Atypical Antipsychotic Drugs</a>&nbsp;<cite>(OEI-07-08-00151)</cite></li>
<li><a href="/oei/reports/oei-05-07-00300.pdf">Louisiana Medicaid Payments and Services Related to Hurricanes Katrina and Rita: Data Compendium</a>&nbsp;<cite>(OEI-05-07-00300)</cite></li> 
<li><a publish_date="06/07/2012" href="/oei/reports/oei-05-12-00060.asp">Part D Plans Generally Include Drugs Commonly Used by Dual Eligibles:  2012</a>&nbsp;<cite>(OEI-05-12-00060)</cite></li>
<li><a href="/oei/reports/oei-02-09-00600.asp">Retail Pharmacies With Questionable Part D Billing</a>&nbsp;<cite>(OEI-02-09-00600)</cite></li> 
<li><a publish_date="04/20/2012" href="/oei/reports/oei-03-10-00360.asp">Medicare Payments for Drugs Used To Treat Wet Age Related Macular Degeneration</a>&nbsp;<cite>(OEI-03-10-00360)</cite></li>
<li><a publish_date="01/10/2012" href="/oei/reports/oei-03-10-00280.asp">Comparison of Average Sales Prices to Widely Available Market Prices for Selected Drugs</a>&nbsp;<cite>(OEI-03-10-00280)</cite></li>
<li><a href="/oei/reports/oei-03-12-00020.asp">Comparison of Second-Quarter 2011 Average Sales Prices and Average Manufacturer Prices:  Impact on Medicare Reimbursement for Fourth Quarter 2011</a>&nbsp;<cite>(OEI-03-12-00020)</cite></li>
<li><a publish_date="12/20/2011" href="/oei/reports/oei-03-09-00330.asp">Audits of Medicare Prescription Drug Plan Sponsors</a>&nbsp;<cite>(OEI-03-09-00330)</cite></li>
<li><a publish_date="11/14/2011" href="/oei/reports/oei-07-08-00152.asp">Ensuring That Medicare Part D Reimbursement Is Limited to Drugs Provided for Medically Accepted Indications</a>&nbsp;<cite>(OEI-07-08-00152)</cite></li>
<li><a href="/oei/reports/oei-03-09-00520.asp">Zone Program Integrity Contractors' Data Issues Hinder Effective Oversight</a>&nbsp;<cite>(OEI-03-09-00520)</cite></li>
<li><a href="/oei/reports/oei-03-11-00410.asp">Comparison of Average Sales Prices and Average Manufacturer Prices: An Overview of 2010</a>&nbsp;<cite>(OEI-03-11-00410)</cite></li>
<li><a publish_date="08/18/2010" href="/oei/reports/oei-03-10-00260.asp">Medicaid Brand-Name Drugs:  Rising Prices Are Offset by Manufacturer Rebates</a>&nbsp;<cite>(OEI-03-10-00260)</cite></li> 
<li><a publish_date="08/16/2010" href="/oei/reports/oei-03-10-00320.asp">Higher Rebates for Brand-Name Drugs Result in Lower Costs for Medicaid Compared to Medicare Part D</a>&nbsp;<cite>(OEI-03-10-00320)</cite></li>
<li><a publish_date="08/12/2010" href="/oei/reports/oei-03-11-00540.asp">Comparison of First-Quarter 2011 Average Sales Prices and Average Manufacturer Prices:  Impact on Medicare Reimbursement for Third Quarter 2011</a>&nbsp;<cite>(OEI-03-11-00540)</cite></li> 
<li><a publish_date="07/27/2010" href="/oei/reports/oei-01-10-00060.asp">Medicare Prescription Drug Sponsors' Training To Prevent Fraud, Waste, and Abuse</a>&nbsp;<cite>(OEI-01-10-00060)</cite></li>
<li><a publish_date="07/25/2011" href="/oei/reports/oei-03-11-00360.asp">Comparison of Fourth-Quarter 2010 Average Sales Prices and Average Manufacturer Prices:  Impact on Medicare Reimbursement for Second Quarter 2011</a>&nbsp;<cite>(OEI-03-11-00360)</cite></li>
<li><a publish_date="07/18/2011" href="/oei/reports/oei-03-11-00060.asp">Replacing Average Wholesale Price:  Medicaid Drug Payment Policy</a>&nbsp;<cite>(OEI-03-11-00060)</cite></li>
<li><a publish_date="06/27/2011" href="/oei/reports/oei-03-09-00410.asp">States' Collection of Medicaid Rebates for Physician-Administered Drugs</a>&nbsp;<cite>(OEI-03-09-00410)</cite></li>
<li><a publish_date="06/15/2011" href="/oei/reports/oei-05-09-00321.asp">State Medicaid Policies and Oversight Activities Related to 340B-Purchased Drugs</a>&nbsp;<cite>(OEI-05-09-00321)</cite></li> 
<li><a publish_date="04/27/2011" href="/oei/reports/oei-05-10-00390.asp">Part D Plans Generally Cover Drugs Commonly Used By Dual Eligibles</a>&nbsp;<cite>(OEI-05-10-00390)</cite></li>
<li><a publish_date="04/25/2011" href="/oei/reports/oei-03-10-00380.asp">Comparison of Average Sales Prices and Average Manufacturer Prices:  An Overview of 2009</a>&nbsp;<cite>(OEI-03-10-00380)</cite></li> 
<li><a publish_date="03/04/2011" href="/oei/reports/oei-02-08-00050.asp">Concerns With Rebates in the Medicare Part D Program</a>&nbsp;<cite>(OEI-02-08-00050)</cite></li>
<li><a publish_date="02/15/2011" href="/oei/reports/oei-03-11-00030.asp">Comparison of Second-Quarter 2010 Average Sales Prices and Average Manufacturer Prices:  Impact on Medicare Reimbursement for Fourth Quarter 2010</a>&nbsp;<cite>(OEI-03-11-00030)</cite></li>
<li><a publish_date="01/11/2011" href="/oei/reports/oei-03-09-00510.pdf">Medicare Payments for Newly Available Generic Drugs</a> <cite>(OEI-03-09-00510)</cite></li>
<li><a publish_date="12/23/2010" href="/oei/reports/oei-03-09-00530.asp">Questionable Billing for Brand-Name Inhalation Drugs in South Florida</a> <cite>(OEI-03-09-00530)</cite></li>
<li><a publish_date="11/26/2010" href="/oei/reports/oei-03-08-00500.asp">FDA's Approval Status of Drugs Paid for by Medicaid</a> <cite>(OEI-03-08-00500)</cite></li> 
<li><a publish_date="11/18/2010" target="_blank" href="/oei/reports/oei-02-10-00120.pdf">Medicare Part D Pharmacy Discounts for 2008</a> <cite>(OEI-02-10-00120)</cite></li>
<li><a target="_blank" publish_date="11/02/2010" href="/oei/reports/OEI-03-10-00440.pdf">Comparison of First-Quarter 2010 Average Sales Prices and Average Manufacturer Prices:  Impact on Medicare Reimbursement for Third Quarter 2010</a> <cite>(OEI-03-10-00440)</cite></li>
<li><a target="_blank" publish_date="10/25/2010" href="/oei/reports/oei-03-09-00420.pdf">Payment for Drugs Under the Hospital Outpatient Prospective Payment System</a> <cite>(OEI-03-09-00420)</cite></li>
<li><a target="_blank" publish_date="09/28/2010" href="/oei/reports/oei-03-09-00060.pdf">Drug Manufacturers? Noncompliance With Average Manufacturer Price Reporting Requirements</a> <cite>(OEI-03-09-00060)</cite></li>
<li><a target="_blank" publish_date="07/02/2010" href="/oei/reports/oei-03-10-00350.pdf">Comparison of Fourth-Quarter 2009 Average Sales Prices and Average Manufacturer Prices:  Impact on Medicare Reimbursement for Second Quarter 2010</a> <cite>(OEI-03-10-00350)</cite></li>
<li><a publish_date="04/27/2010" href="/oei/reports/oei-03-10-00150.pdf">Comparison of Third-Quarter 2009 Average Sales Prices and Average Manufacturer Prices:  Impact on Medicare Reimbursement for First Quarter 2010</a> <cite> (OEI-03-10-00150)</cite></li>
<li><a publish_date="02/19/2010" href="/oei/reports/oei-03-09-00350.pdf">Comparison of Average Sales Prices and Average Manufacturer Prices:  An Overview of 2008</a> (OEI-03-09-00350)</li>
<li><a publish_date="02/19/2010" href="/oei/reports/oei-03-08-00480.pdf">Average Sales Prices:  Manufacturer Reporting and CMS Oversight</a> (OEI-03-08-00480)</li>
<li><a publish_date="01/27/2010" href="/oei/reports/oei-03-09-00640.pdf">Comparison of Second-Quarter 2009 Average Sales Prices and Average Manufacturer Prices:  Impact on Medicare Reimbursement for Fourth Quarter 2009</a> <cite>(OEI-03-09-00640)</cite></li>
<li><a publish_date="01/27/2010" href="/oei/reports/oei-03-09-00340.pdf">Comparison of Fourth-Quarter 2008 Average Sales Prices and Average Manufacturer Prices:  Impact on Medicare Reimbursement for Second Quarter 2009</a> <cite>(OEI-03-09-00340)</cite> </li>

<li><a publish_date="01/27/2010" href="/oei/reports/oei-03-09-00490.pdf">Comparison of First-Quarter 2009 Average Sales Prices and Average Manufacturer Prices:  Impact on Medicare Reimbursement for Third Quarter 2009</a> <cite>(OEI-03-09-00490)</cite></li>

<li><a publish_date="01/20/2010" href="/oei/reports/oei-03-08-00490.pdf">A Comparison of Medicaid Federal Upper Limit Amounts to Acquisition Costs, Medicare Payment Amounts, and Retail Prices</a> (OEI-03-08-00490)</li>
<li><a publish_date="01/20/2010" href="/oei/reports/oei-03-07-00740.pdf">Outlier Average Manufacturer Prices in the Federal Upper Limit Program</a> (OEI-03-07-00740)</li>
<li><a href="/oei/reports/oei-03-08-00420.pdf">Medicare Drug Integrity Contractors? Identification of Potential Part D Fraud and Abuse</a> <cite>(OEI-03-08-00420)</cite></li>
<li><a href="/oei/reports/oei-03-07-00440.pdf">Beneficiary Utilization of Albuterol and Levalbuterol Under Medicare Part B</a>  <cite>(OEI-03-07-00440)</cite></li>
<li><a href="/oei/reports/oei-03-08-00300.pdf">Accuracy of Drug Categorizations for Medicaid Rebates</a> <cite>(OEI-03-08-00300)</cite></li>
<li><a href="/oei/reports/oei-03-08-00290.pdf">Aberrant Claim Patterns for Inhalation Drugs in South Florida </a> <cite>(OEI-03-08-00290)</cite></li>
<li><a href="/oei/reports/oei-03-09-00150.pdf">Comparison of Third-Quarter 2008 Average Sales Prices and Average Manufacturer Prices:  Impact on Medicare Reimbursement for First Quarter 2009</a> <cite>(OEI-03-09-00150)</cite></li>
<li><a href="/oei/reports/oei-03-07-00350.pdf">Comparing Pharmacy Reimbursement:  Medicare Part D to Medicaid</a> <cite>(OEI-03-07-00350)</cite></li>
<li><a href="/oei/reports/oei-03-09-00050.pdf">Comparison of Second-Quarter 2008 Average Sales Prices and Average Manufacturer Prices:  Impact on Medicare Reimbursement for Fourth Quarter 2008</a> <cite>(OEI-03-09-00050)</cite></li>
<li><a href="/oei/reports/oei-03-08-00530.pdf">Comparison of First-Quarter 2008 Average Sales Prices and Average Manufacturer Prices:  Impact on Medicare Reimbursement for Third Quarter 2008</a>  <cite>(OEI-03-08-00530)</cite></li>
<li><a href="/oei/reports/oei-03-08-00450.pdf">Comparison of Average Sales Prices and Average Manufacturer Prices:  An Overview of 2007</a> <cite>(OEI-03-08-00450)</cite></li>
<li><a href="/oei/reports/oei-05-07-00490.pdf">Comparing Special Needs Plan Beneficiaries to Other Medicare Advantage Prescription Drug Plan Beneficiaries</a> <cite>(OEI-05-07-00490)</cite></li>
<li><a href="/oei/reports/oei-05-07-00560.pdf">Centers for Medicare &amp; Medicaid Services Audits of Medicare Part D Bids</a> <cite>(OEI-05-07-00560)</cite></li>
<li><a href="/oei/reports/oei-03-08-00230.pdf">Oversight of Prescription Drug Plan Sponsors? Compliance Plans</a> <cite>(OEI-03-08-00230)</cite></li>
<li><a href="/oei/reports/oei-03-07-00380.pdf">Medicare Drug Plan Sponsors? Identification of Potential Fraud and Abuse</a> <cite>(OEI-03-07-0380)</cite></li>
<li><a href="/oei/reports/oei-03-08-00310.pdf">Medicare Payment for Irinotecan</a> <cite>(OEI-03-08-00310)</cite></li>
<li><a href="/oei/reports/oei-03-08-00340.pdf">Comparison of Fourth-Quarter 2007 Average Sales Prices and Average Manufacturer Prices:  Impact on Medicare Reimbursement for Second-Quarter 2008</a> <cite>(OEI-03-08-00340)</cite></li>
<li><a href="/oei/reports/oei-03-07-00190.pdf">A Comparison of Average Sales Prices to Widely Available Market Prices for Inhalation Drugs</a> <cite>(OEI-03-07-00190)</cite></li>
<li><a href="/oei/reports/oei-03-08-00130.pdf">Comparison of Third-Quarter 2007 Average Sales Prices to Average Manufacturer Prices: Impact on Medicare Reimbursement for First-Quarter 2008</a> <cite>(OEI-03-08-00130)</cite></li>
<li><a href="/oei/reports/oei-03-08-00010.pdf">Comparison of Second-Quarter 2007 Average Sales Prices and Average Manufacturer Prices:  Impact on Medicare Reimbursement for Fourth Quarter 2007 </a> <cite>(OEI-03-08-00010)</cite></li>
<li><a href="/oei/reports/oei-05-07-00130.pdf">Generic Drug Utilization in the Medicare Part D Program</a> <cite>(OEI-05-07-00130)</cite></li>
<li><a href="/oei/reports/oei-03-07-00530.pdf">Comparison of First-Quarter 2007 Average Sales Prices to Average Manufacturer Prices:  Impact on Medicare Reimbursement for Third Quarter 2007 </a> <cite>(OEI-03-07-00530)</cite></li>
<li><a href="/oei/reports/oei-03-07-00140.pdf">Comparison of Third-Quarter 2006 Average Sales Prices to Average Manufacturer Prices: Impact on Medicare Reimbursement for First Quarter 2007</a> <cite>(OEI-03-07-00140)</cite></li>
<li><a href="/oei/reports/oei-05-06-00320.pdf">Retail Pharmacy Participation in Medicare Part D Prescription Drug Plans in 2006</a> <cite>(OEI-05-06-00320)</cite></li>
<li><a href="/oei/reports/oei-03-06-00400.pdf">Deficit Reduction Act of 2005: Impact on the Medicaid Federal Upper Limit Program</a> <cite>(OEI-03-06-00400)</cite></li>
<li><a href="/oei/reports/oei-03-06-00350.pdf">Examining Fluctuations in Average Manufacturer Prices</a> <cite>(OEI-03-06-00350)</cite></li>
<li><a href="/oei/reports/oei-03-06-00490.pdf">States? Use of New Drug Pricing Data in the Medicaid Program</a> <cite>(OEI-03-06-00490)</cite></li>
<li><a href="/oei/reports/oei-03-05-00404.pdf">Intravenous Immune Globulin: Medicare Payment and Availability</a> <cite>(OEI-03-05-00404)</cite></li>
<li><a href="/oei/reports/oei-03-06-00370.pdf">Comparison of Fourth Quarter 2005 Average Sales Prices to Average Manufacturer Prices: Impact on Medicare Reimbursement for Second Quarter 2006</a> <cite>(OEI-03-06-00370; 07/06)</cite></li>
<li><a href="/oei/reports/oei-05-02-00073.pdf">Review of 340B Prices</a> <cite>(OEI-05-02-00073; 07/06)</cite></li>
<li><a href="/oei/reports/oei-05-05-00360.pdf">Generic Drug Utilization in State Medicaid Programs</a> <cite>(OEI-05-05-00360; 07/06)</cite></li>
<li><a href="/oei/reports/oei-03-05-00430.pdf">A Comparison of Average Sales Price to Widely Available Market Prices: Fourth Quarter 2005</a> <cite>(OEI-03-05-00430; 06/06)</cite></li>
<li><a href="/oei/reports/oei-03-04-00430.pdf">Monitoring Medicare Part B Drug Prices: A Comparison of Average Sales Prices to Average Manufacturer Prices</a> <cite>(OEI-03-04-00430; 05/06)</cite></li>
<li><a href="/oei/reports/oei-03-06-00200.pdf">Medicare Reimbursement for New End Stage Renal Disease Drugs</a> <cite>(OEI-03-06-00200; 03/06)</cite></li>
<li><a href="/oei/reports/oei-03-05-00310.pdf">Calculation of Volume-Weighted Average Sales Price for Medicare Part B Prescription Drugs</a> <cite>(OEI-03-05-00310; 03/06)</cite></li>
<li><a href="/oei/reports/oei-05-02-00072.pdf">Deficiencies in the Oversight of the 340B Drug Pricing Program</a> <cite>(OEI-05-02-00072; 10/05)</cite></li>
<li><a href="/oei/reports/oei-01-05-00090.pdf">Review of Services Provided by Inhalation Drug Suppliers</a> <cite>(OEI-01-05-00090; 09/05)</cite></li>
<li><a href="/oei/reports/oei-03-05-00350.pdf">How Inflated Published Prices Affect Drugs Considered for the Federal Upper Limit List  </a> <cite>(OEI-03-05-00350; 09/05)</cite></li>
<li><a href="/oei/reports/oei-03-05-00110.pdf">Comparison of Medicaid Federal Upper Limit Amounts to Average Manufacturer Prices</a> <cite>(OEI-03-05-00110; 06/05)</cite></li>
<li><a href="/oei/reports/oei-05-05-00240.pdf">Medicaid Drug Price Comparisons: Average Manufacturer Price to Published Prices</a> <cite>(OEI-05-05-00240; 06/05)</cite></li>
<li><a href="/oei/reports/oei-03-05-00200.pdf">Medicaid Drug Price Comparison: Average Sale Price to Average Wholesale Price</a> <cite>(OEI-03-05-00200; 06/05)</cite></li>
<li><a href="/oei/reports/oei-03-04-00320.pdf"> Addition of Qualified Drugs to the Medicaid Federal Upper Limit List</a> <cite>(OEI-03-04-00320; 12/04)</cite></li>
<li><a href="/oei/reports/oei-05-02-00681.pdf">Variation in State Medicaid Drug Prices</a> <cite>(OEI-05-02-00681; 09/04)</cite></li>
<li><a href="/oei/reports/oei-05-02-00071.pdf">Deficiencies in the 340B Drug Discount Program's Database</a> <cite>(OEI-05-02-00071; 06/04)</cite></li>
<li><a href="/oei/reports/oei-05-02-00070.pdf">Appropriateness of 340B Drug Prices</a> <cite>(OEI-05-02-00070; 06/04)</cite></li>
<li><a href="/oei/reports/oei-03-04-00120.pdf">Medicare Reimbursement for Existing End-Stage Renal Disease Drugs</a> <cite>(OEI-03-04-00120; 05/04)</cite></li>
<li><a href="/oei/reports/oei-03-02-00660.pdf">Medicaid Rebates for Physician-Administered Drugs</a> <cite>(OEI-03-02-00660; 04/04)</cite></li>
<li><a href="/oei/reports/oei-03-02-00670.pdf">Omission of Drugs from the Federal Upper Limit List in 2001</a> <cite>(OEI-03-02-00670; 03/04)</cite></li>
<li><a href="/oei/reports/oei-03-03-00250.pdf">Medicare Reimbursement for Lupron</a> <cite>(OEI-03-03-00250; 01/04)</cite></li>
<li><a href="/oei/reports/oei-03-03-00510.pdf">Update: Excessive Medicare Reimbursement for Albuterol</a> <cite>(OEI-03-03-00510; 01/04)</cite></li>
<li><a href="/oei/reports/oei-03-03-00520.pdf">Update: Excessive Medicare Reimbursement for Ipratropium Bromide</a> <cite>(OEI-03-03-00520; 01/04)</cite></li>
<li><a href="/oei/reports/oei-05-02-00680.pdf">State Strategies to Contain Medicaid Drug Costs</a> <cite>(OEI-05-02-00680)</cite></li>
<li><a href="/oei/reports/oei-05-02-00080.pdf">Medicaid's Mental Health Drug Expenditures</a> <cite>(OEI-05-02-00080; 08/03)</cite></li>
<li><a href="/oei/reports/oei-01-01-00590.pdf">FDA's Review Process for New Drug Applications: A Management Review</a> <cite>(OEI-01-01-00590; 03/02)</cite></li>
<li><a href="/oei/reports/oei-03-01-00411.pdf">Excessive Medicare Reimbursement for Ipratropium Bromide</a> <cite>(OEI-03-01-00411; 03/02)</cite></li>
<li><a href="/oei/reports/oei-02-00-00490.pdf">Psychotropic Drug Use in Nursing Homes</a> <cite>(OEI-02-00-00490; 11/01)</cite></li>
<li><a href="/oei/reports/oei-02-00-00491.pdf">Psychotropic Drug Use in Nursing Homes: Supplemental Information?10 Case Studies</a> <cite>(OEI-02-00-00491; 11/01)</cite></li>
<li><a href="/oei/reports/oei-03-01-00010.pdf">Medicaid's Use of Revised Average Wholesale Prices</a> <cite>(OEI-03-01-00010; 10/01)</cite></li>
<li><a href="/oei/reports/oei-03-00-00030.pdf">Medicaid Recovery of Pharmacy Payments from Liable Third Parties</a> <cite>(OEI-03-00-00030; 08/01)</cite></li>
<li><a href="/oei/reports/oei-05-99-00611.pdf">Cost Containment of Medicaid HIV/AIDS Drug Expenditures</a> <cite>(OEI-05-99-00611; 07/01)</cite></li>
<li><a href="/oei/reports/oei-09-00-00380.pdf">The Orphan Drug Act: Implementation and Impact</a> <cite>(OEI-09-00-00380; 05/01)</cite></li>
<li><a href="/oei/reports/oei-01-00-00180.pdf">Adverse Event Reporting System for Dietary Supplements: An Inadequate Safety Valve</a> <cite>(OEI-01-00-00180; 04/01)</cite></li>
<li><a href="/oei/reports/oei-03-00-00310.pdf">Medicare Reimbursement of Prescription Drugs</a> <cite>(OEI-03-00-00310; 1/01)</cite></li>
<li><a href="/oei/reports/oei-05-99-00610.pdf">AIDS Drug Assistance Program Cost Containment Strategies</a> <cite>(OEI-05-99-00610; 9/00)</cite></li>
<li><a href="/oei/reports/oei-03-00-00020.pdf">Medicare Reimbursement of End Stage Renal Disease Drugs</a> <cite>(OEI-03-00-00020; 6/00)</cite></li>
<li><a href="/oei/reports/oei-03-00-00311.pdf">Medicare Reimbursement of Albuterol</a> <cite>(OEI-03-00-00311; 6/00)</cite></li>
<li><a href="/oei/reports/oei-07-98-00460.pdf">Medicare Licensing Requirements for Prescription Drug Suppliers</a> <cite>(OEI-07-98-00460; 5/99)</cite></li>
<li><a href="/oei/reports/oei-09-97-00380.pdf">FDA Warning Letters: Trends and Perspectives</a> <cite>(OEI-09-97-00380; 2/99)</cite></li>
<li><a href="/oei/reports/oei-09-97-00381.pdf">FDA Warning Letters: Timeliness And Effectiveness</a> <cite>(OEI-09-97-00381; 2/99)</cite></li>
<li><a href="/oei/reports/oei-03-97-00290.pdf">Excessive Medicare Payments for Prescription Drugs</a> <cite>(OEI-03-97-00290; 12/97)</cite></li>
<li><a href="/oei/reports/oei-03-97-00293.pdf">Comparing Drug Reimbursement: Medicare and Department of Veterans Affairs</a> <cite>(OEI-03-97-00293; 11/98)</cite></li>
<li><a href="/oei/reports/oei-03-97-00510.pdf">The Impact of High-Priced Generic Drugs on Medicare and Medicaid</a> <cite>(OEI-03-97-00510; 8/98)</cite></li>
<li><a href="/oei/reports/oei-06-96-00080.pdf">Prescription Drug Use In Nursing Homes - Report 1 - An Introduction Based on Texas</a> <cite>(OEI-06-96-00080; 11/97)</cite></li>
<li><a href="/oei/reports/oei-06-96-00081.pdf">Prescription Drug Use In Nursing Homes - Report 2 - An Inside View by Consultant Pharmacists</a> <cite>(OEI-06-96-00081; 11/97)</cite></li>
<li><a href="/oei/reports/oei-06-96-00082.pdf">Prescription Drug Use In Nursing Homes - Report 3 - A Pharmaceutical Review and Inspection Recommendations</a> <cite>(OEI-06-96-00082; 11/97)</cite></li>
<li><a href="/oei/reports/oei-03-94-00391.pdf">Questionable Practices Involving Nebulizer Drug Therapy</a> <cite>(OEI-03-94-00391; 3/97)</cite></li>
<li><a href="/oei/reports/oei-03-94-00390.pdf">Payments for Prescription Drugs Used with Nebulizers</a> <cite>(OEI-03-94-00390; 2/96)</cite></li>
<li><a href="/oei/reports/oei-03-94-00392.pdf">A Comparison of Albuterol Sulfate Prices</a> <cite>(OEI-03-94-00392; 6/96)</cite></li>
<li><a href="/oei/reports/oei-03-94-00393.pdf">Suppliers' Acquisition Costs for Albuterol Sulfate</a> <cite>(OEI-03-94-00393; 6/96)</cite></li>
<li><a href="/oei/reports/oei-03-95-00420.pdf">Appropriateness of Medicare Prescription Drug Allowances</a> <cite>(OEI-03-95-00420; 5/96)</cite></li>
<li><a href="/oei/reports/oei-03-94-00760.pdf">Postmarketing Studies of Prescription Drugs</a> <cite>(OEI-03-94-00760; 5/96)</cite></li>
<li><a href="/oei/reports/oei-03-94-00090.pdf">Medicaid Payments for Less-Than-Effective Drugs</a> <cite>(OEI-03-94-00090; 8/94)</cite></li>
<li><a href="/oas/reports/region6/69300008.pdf">Medicaid Program Savings Through the Use of Therapeutically Equivalent Drugs</a> <cite>(OEI-03-94-00080; 7/94)</cite></li>
<li><a href="/oei/reports/oei-12-91-00490.pdf">Multiple Copy Prescription Programs: State Experiences</a> <cite>(OEI-12-91-00490; 6/92)</cite></li>
<li><a href="/oei/reports/oei-03-91-00470.pdf">Comparison of Reimbursement Prices for Multiple-Source Prescription Drugs in the United States and Canada</a> <cite>(OEI-03-91-00470; 8/91)</cite></li>
<li><a href="/oei/reports/oei-12-90-00800.pdf">Strategies to Reduce Medicaid Drug Expenditures</a> <cite>(OEI-12-90-00800; 3/91)</cite></li>
<li><a href="/oei/reports/oei-04-89-89122.pdf">Reducing Medication Problems of the Elderly</a> <cite>(OEI-04-89-89122; 11/90)</cite></li>
<li><a href="/oei/reports/oei-04-89-89121.pdf">Medication Regimens: Causes of Non-Compliance</a> <cite>(OEI-04-89-89121; 6/90)</cite></li>
<li><a href="/oei/reports/oai-04-90-00990.pdf">Rural Georgia Pharmacy Closures</a> <cite>(OAI-04-90-00990; 12/89)</cite></li>
<li><a href="/oei/reports/oai-01-88-00980.pdf">Medicare Drug Utilization Review</a> <cite>(OAI-01-88-00980; 5/89)</cite></li>
<li><a href="/oei/reports/oei-01-90-00481.pdf">Prescription Drug Promotion Involving Payments and Gifts: Physicians' Perspectives</a> <cite>(OEI-01-90-00481; 7/92)</cite></li>
<li><a href="/oei/reports/oei-01-90-00482.pdf">Prescription Drug Advertisements in Medical Journals</a> <cite>(OEI-01-90-00482; 6/92)</cite></li>
<li><a href="/oei/reports/oei-07-94-00631.pdf">FDA's Urgent Notices</a> <cite>(OEI-07-94-00631; 7/96)</cite></li>
<li><a href="/oei/reports/oei-12-92-00200.pdf"><acronym title="Office of Inspector General">OIG</acronym>Oversight of FDA Activities: A Summary Report</a> <cite>(OEI-12-92-00200; 2/92)</cite></li>
<li><a href="/oei/reports/oei-03-90-02300.pdf">The FDA Prescription Drug File</a> <cite>(OEI-03-90-02300; 11/91)</cite></li>
<li><a href="/oei/reports/oei-03-90-02301.pdf">Computer Support for FDA's Drug Registration and Listing System</a> <cite>(OEI-03-90-02301; 11/91)</cite></li>
<li><a href="/oei/reports/oei-12-90-01000.pdf">Hospital Reporting of Adverse Drug Reactions</a> <cite>(OEI-12-90-01000; 8/91)</cite></li>
<li><a href="/oei/reports/oei-01-90-00480.pdf">Promotion of Prescription Drugs Through Payments and Gifts</a> <cite>(OEI-01-90-00480; 8/91)</cite></li>
<li><a href="/oei/reports/oei-01-89-89010.pdf">Symposium on Drug Utilization Review Issues - Summary Report</a> <cite>(OEI-01-89-89010; 8/90)</cite></li>
<li><a href="/oei/reports/oei-12-90-02020.pdf">Implementing User Fees in the Food and Drug Administration: A Case Study</a> <cite>(OEI-12-90-02020; 7/90)</cite></li>
<li><a href="/oei/reports/oei-12-90-00770.pdf">Perspectives of Drug Manufacturers: Abbreviated New Drug Applications</a> <cite>(OEI-12-90-00770; 2/90)</cite></li>
<li><a href="/oei/reports/oei-12-90-00771.pdf">Perspectives of Drug Manufacturers: Investigational New Drug and New Drug Applications</a> <cite>(OEI-12-90-00771; 2/90)</cite></li>
<li><a href="/oei/reports/oai-01-88-00590.pdf">Physician Drug Dispensing: An Overview of State Regulation</a> <cite>(OAI-01-88-00590; 5/89)</cite></li>
</ul>


<p>
 <a class="back"  href="/reports-and-publications/oei/subject_index.asp#D" title="Go back">Back</a>  <a class="top"  href="#top">Top</a></p>
<!--===============  [ *** ]  ===============-->
<h2>Drug Utilization Review</h2>
<ul class="simplegray lowmargin overlinked">
<li class="crossref">see: <a href="#drugs">Drugs and Drug Industry</a></li>
</ul>



<p><a name="durp"></a>
 <a class="back"  href="/reports-and-publications/oei/subject_index.asp#D" title="Go back">Back</a>  <a class="top"  href="#top">Top</a></p>
<!--===============  [ *** ]  ===============-->
<h2>Drug Use Review Programs</h2>
<ul class="simplegray lowmargin overlinked">
<li><a href="/oei/reports/oei-01-92-00800.pdf">Medicaid Drug Use Review Programs: Lessons Learned by States</a> <cite>(OEI-01-92-00800; 5/95)</cite></li>
</ul>



<p><a name="dumping"></a>
 <a class="back"  href="/reports-and-publications/oei/subject_index.asp#D" title="Go back">Back</a>  <a class="top"  href="#top">Top</a></p>
<!--===============  [ *** ]  ===============-->
<h2>Dumping</h2>
<ul class="simplegray lowmargin overlinked">
<li class="crossref">see also: <a href="/reports-and-publications/oei/h.asp#hospitals">Hospitals</a></li>
<li><a href="/oei/reports/oai-12-88-00831.pdf">Patient Dumping After COBRA: U.S. Department of Health and Human Services Response to Complaints</a> <cite>(OAI-12-88-00831; 12/88)</cite></li>
<li><a href="/oei/reports/oai-12-88-00830.pdf">Patient Dumping After COBRA: Assessing the Incidence and the Perspectives of Health Care Professionals</a> <cite>(OAI-12-88-00830; 8/88)</cite></li>
<li><a href="/oei/reports/oai-05-86-00050.pdf">Inappropriate Discharges and Transfers</a> <cite>(OAI-05-86-00050; 3/86)</cite></li>
<li><a href="/oei/reports/oei-05-90-00260.pdf">Public Health Service's Oversight of the Hill-Burton Program</a> <cite>(OEI-05-90-00260; 8/92)</cite></li>
<li><a href="/oei/reports/oei-05-90-00261.pdf">Office for Civil Rights' Oversight of the Hill-Burton Program</a> <cite>(OEI-05-90-00261; 8/92)</cite></li>
</ul>



<p><a name="dmerc"></a>
 <a class="back"  href="/reports-and-publications/oei/subject_index.asp#D" title="Go back">Back</a>  <a class="top"  href="#top">Top</a></p>
<!--===============  [ *** ]  ===============-->
<h2>Durable Medical Equipment Regional Carriers (DMERC)</h2>
<ul class="simplegray lowmargin overlinked">
<li class="crossref">see also: <a href="/reports-and-publications/oei/m.asp#mde">Medical Devices and Equipment</a></li>
<li><a href="/oei/reports/oei-03-94-00793.pdf">Medicare Part B Allowances for Wound Care Supplies</a> <cite>(OEI-03-94-00793; 6/98)</cite></li>
<li><a href="/oei/reports/oei-02-96-00200.pdf">Medicare Beneficiary Satisfaction with DMERC Services</a> <cite>(OEI-02-96-00200; 6/97)</cite></li>
</ul>

<p>
 <a class="back"  href="/reports-and-publications/oei/subject_index.asp#D" title="Go back">Back</a>  <a class="top"  href="#top">Top</a></p>
<!--===============  [ *** ]  ===============-->
<h2>Durable Medical Equipment</h2>
<ul class="simplegray lowmargin overlinked">
<li class="crossref">see: <a href="/reports-and-publications/oei/m.asp#mde">Medical Devices and Equipment</a></li>
</ul>

<!-- /OEI Subject Box -->
</div>



					
					
					<p><a class="top" href="#top">Top</a></p>
					<p><a href="/reports-and-publications/index.asp">Return to Reports and Publications</a></p>

				</div><!-- leftContentInterior -->
			</div>	<!-- leftSideInterior ends -->
			<div id="rightSide">
				<!--#include virtual="/layout/im-looking-for.asp" -->
				<!-- #include virtual="/layout/sub-navigation/subnavigation-reports-and-publications.asp" -->
				<!--#include virtual="/layout/exclusions-database.asp" -->
				<!--#include virtual="/layout/report-fraud.asp" -->
				<div class="clearPadding"></div>
				<!--#include virtual="/layout/email-alerts.asp" -->
			</div><!-- rightSide ends -->
			<div class="clear"></div>
		</div><!-- mainBody ends -->
	</div><!-- textReset ends -->
</div><!-- bodyContainer ends -->
<div id="footerContainer">
	<!--#include virtual="/layout/footer-top.asp" -->
</div><!-- footerContainer ends -->
<div id="footerBottomContainer">
	<!-- #include virtual="/layout/footer-bottom.asp" -->
</div><!-- footerBottomContainer -->
</body>
</html>
